BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:OPKO Health readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies OPKO Health's drugs run\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07494045-881@assetmemo.bio
DTSTAMP:20261121T005943Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Rayaldee (Extended-release calcifediol): Phase 2 readout est. (NCT0
 7494045)
DESCRIPTION:Rayaldee (Extended-release calcifediol)\, phase 2\, Chronic Kid
 ney Disease.\nStudy: Pharmacokinetics\, Pharmacodynamics\, Safety and Tole
 rability Evaluation of CTAP101 Extended-release Capsules in Pediatric Part
 icipants\nEstimated primary completion: October 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/extended-release-calcifediol#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07494045
URL:https://assetmemo.bio/drug/extended-release-calcifediol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07512427-6935@assetmemo.bio
DTSTAMP:20261121T005943Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:OPK-88006: Phase 1/2 readout est. (NCT07512427)
DESCRIPTION:OPK-88006\, phase 1/2\, MASH / NASH.\nStudy: Phase 1/2 Study of
  OPK-88006 in Healthy and Presumed MASH Participants\nEstimated primary co
 mpletion: December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/opk-88006#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07512427
URL:https://assetmemo.bio/drug/opk-88006#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
